Hydrolytic activity is essential for aceclofenac to inhibit cyclooxygenase in rheumatoid synovial cells

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 676-681

  Yamazaki, Ryuta ^a   Kawai, Shinichi ^b   Matsumoto, Tsuneo ^a   Matsuzaki, Takeshi ^a   Hashimoto, Shusuke ^a   Yokokura, Teruo ^a   Okamoto, Renzo ^c   Koshino, Tomihisa ^c   Mizushima, Yutaka ^b  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYACECLOFENAC; ACECLOFENAC; DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CELL CULTURE; CONFERENCE PAPER; DRUG HYDROLYSIS; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; RHEUMATIC DISEASE; SYNOVIOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BLOTTING, WESTERN; CELLS, CULTURED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; DINOPROSTONE; HUMANS; HYDROLYSIS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; MEMBRANE PROTEINS; MICROSOMES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SYNOVIAL MEMBRANE;

EID: 0032903184     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (24)

1. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL and Hunder GG (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324.
2. Ballesteros R, Ansoleaga JJ and Tapounet R (1990) The Efficacy and tolerance of aceclofenac in rheumatoid arthritis: A double-blind study v. placebo. Clin Trials J 27:12-19.
3. Bort R, Ponsoda X, Carrasco E, Gómez-Lechón MJ and Castell JV (1996a) Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human. Drug Metab Dispos 24:969-975.
4. Bort R, Ponsoda X, Carrasco E, Gómez-Lechón MJ and Castell JV (1996b) Metabolism of aceclofenac in humans. Drug Metab Dispos 24:834-841.
5. Brennan FM, Chantry D, Jackson A, Maini R and Feldmann M (1989) Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247.
6. 2-prostaglandin levels in synovial fluid and in serum. Clin Trials J 25:144-151.
7. Dayer J-M, Krane SM, Russell RGG and Robinson DR (1976) Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells. Proc Natl Acad Sci USA 73:945-949.
8. Dayer J-M, Robinson DR and Krane SM (1977) Prostaglandin production by rheumatoid synovial cells: Stimulation by a factor from human mononuclear cells. J Exp Med 145:1399-1404.
9. Díaz C, de la Serna AR, Geli C and Gras X (1996) Efficacy and tolerability of aceclofenac versus diclofenac in the treatment of knee osteoarthritis: A multicentre study. Eur J Rheumatol Inflamm 16:17-22.
10. Gonzälez E, de la Cruz C, de Nicoläs R, Egido J and Herrero-Beaumont G (1994) Long-term effect of nonsteroidal anti-inflammatory drugs on the production of cytokines and other inflammatory mediators by blood cells of patients with osteoarthritis. Agents Actions 41:171-178.
11. Grau M, Guasch J, Montero JL, Felipe A, Carrasco E and Juliá S (1991a) Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac. Arzneim-Forsch 41:1265-1276.
12. Grau M, Montero JL, Guasch J, Felipe A, Carrasco E and Juliá S (1991b) The pharmacological profile of aceclofenac, a new nonsteroidal antiinflammatory and analgesic drug. Agents Actions 32:125-129.
13. 2. Arthritis Rheum 37:653-661.
14. Kawai S, Nishida S, Kato M, Furumaya Y, Okamoto R, Koshino T and Mizushima Y (1998) Comparison of cyclooxygenase-1 and -2 inhibitory activities of various nonsteroidal anti-inflammatory drugs using human synovial cells and platelets. Eur J Pharmacol 347:87-94.
15. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
16. Masferrer JL, Reddy ST, Zweifel BS, Seibert K, Needleman P, Gilbert RS and Herschman HR (1994) In vivo glucocorticoids regulate cyclooxygenase-2 but not cyclooxygenase-1 in peritoneal macrophages. J Pharmacol Exp Ther 270:1340-1344.
17. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ and Vane JR (1994) Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 90:11693-11697.
18. Nielen MWF, Valk AJ, Frei RW and Brinkman UATh (1987) Fully automated sample handling system for liquid chromatography based on pre-column technology and automated cartridge exchange. J Chromatogr 393:69-83.
19. Robinson DR, Tashjian AH Jr and Levine L (1975) Prostaglandin-stimulated bone resorption by rheumatoid synovia: A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 56:1181-1188.
20. Tordjman C, Coge F, Andre N, Rique H, Spedding M and Bonnet J (1995) Characterisation of cyclooxygenase 1 and 2 expression in mouse resident peritoneal macrophages in vitro: Interactions of non steroidal anti-inflammatory drugs with COX2. Biochim Biophys Acta 1256:249-256.
21. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231:232-235.
22. Ward DE, Veys EM, Bowdler JM and Roma J (1995) Comparison of aceclofenac with diclofenac in the treatment of osteoarthritis. Clin Rheumatol 14:656-662.
23. 2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur J Pharmacol 329:181-187.
24. Yanagawa A, Kanemitsu K, Kawai S, Hoshi K, Shimada J and Mizushima Y (1993) Phase I clinical trial of aceclofenac: A placebo controlled double blind study (Abstract). XVIIIth ILAR Congress of Rheumatology 491, Barcelona, Spain, July 4-10, 1993.